Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine

Aim: To evaluate and compare the efficacy of combination treatment using 0.025% atropine and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses to 0.025% atropine and single vision (SV) spectacle lenses in slowing myopia progression in children with myopia. Methods: Randomised controlled...

Descripción completa

Detalles Bibliográficos
Autores: Guemes-Villahoz Noemi, Talavero González Paula, Porras-Ángel Paloma, Bella Gala, Rafael, Ruiz Pomeda, Alicia, Martín García, Beatriz, Hernández García, Elena, GÓMEZ DE LIAÑO SALGADO, CARMEN NUNILA, Shah Rakhee, García Feijoo, Julián, Gómez De Liaño Sánchez, María Rosario
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/132480
Acceso en línea:https://hdl.handle.net/20.500.14352/132480
Access Level:acceso abierto
Palabra clave:617.7-089.243
617.75-053.2
Myopia control
Children
DIMS lenses
Atropine
Óptica y optometría
Óptica oftálmica
Pediatría
2209.15 Optometría
3212 Salud Publica
3201.10 Pediatría
3311.09 Lentes
id ES_abca2ca3c9dfb7ecdf11b086fa9a35b1
oai_identifier_str oai:docta.ucm.es:20.500.14352/132480
network_acronym_str ES
network_name_str España
repository_id_str
spelling Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropineGuemes-Villahoz NoemiTalavero González PaulaPorras-Ángel PalomaBella Gala, RafaelRuiz Pomeda, AliciaMartín García, BeatrizHernández García, ElenaGÓMEZ DE LIAÑO SALGADO, CARMEN NUNILAShah RakheeGarcía Feijoo, JuliánGómez De Liaño Sánchez, María Rosario617.7-089.243617.75-053.2Myopia controlChildrenDIMS lensesAtropineÓptica y optometríaÓptica oftálmicaPediatría2209.15 Optometría3212 Salud Publica3201.10 Pediatría3311.09 LentesAim: To evaluate and compare the efficacy of combination treatment using 0.025% atropine and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses to 0.025% atropine and single vision (SV) spectacle lenses in slowing myopia progression in children with myopia. Methods: Randomised controlled trial conducted on children aged 4-16 years with myopia between -1.00D and -6.00D and astigmatism ≤2.00D. Children were randomly allocated into two groups: 0.025% atropine and SV spectacle lenses treatment group (group A), and 0.025% atropine and DIMS spectacle lenses treatment group (group B). Cycloplegic spherical equivalent refraction (SER) and axial length were measured at baseline, 6 and 12 months. Results: 102 patients completed the 12-month follow-up: n=49 in group A, mean age 9.50±2.78 years and n=53 in group B, mean age 9.90±2.47 years. At 12 months, the mean AL±SD change was 0.18±0.16 mm in group A and 0.07±0.16 mm in group B (mean difference: 0.11, 95% CI: 0.05 to 0.17; p≤0.001). Mean SER±SD progression at 12 months was -0.19±0.42D and -0.09±0.35D in groups A and B, respectively (p=0.13). 39.6% of children in group B had no axial elongation over 12 months compared with 12.2% of the children in group A (p=0.002). Conclusions: Combination treatment with 0.025% atropine and DIMS spectacle lenses is more effective in controlling axial elongation than 0.025% atropine with SV lenses. Although not significant, SER differences between groups were lower in group B. These findings support a potential additive effect of the two treatments.BMJ GroupUniversidad Complutense de Madrid20252025-08-2020252025-08-20journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/132480reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1324802026-06-02T12:44:21Z
dc.title.none.fl_str_mv Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine
title Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine
spellingShingle Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine
Guemes-Villahoz Noemi
617.7-089.243
617.75-053.2
Myopia control
Children
DIMS lenses
Atropine
Óptica y optometría
Óptica oftálmica
Pediatría
2209.15 Optometría
3212 Salud Publica
3201.10 Pediatría
3311.09 Lentes
title_short Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine
title_full Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine
title_fullStr Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine
title_full_unstemmed Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine
title_sort Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine
dc.creator.none.fl_str_mv Guemes-Villahoz Noemi
Talavero González Paula
Porras-Ángel Paloma
Bella Gala, Rafael
Ruiz Pomeda, Alicia
Martín García, Beatriz
Hernández García, Elena
GÓMEZ DE LIAÑO SALGADO, CARMEN NUNILA
Shah Rakhee
García Feijoo, Julián
Gómez De Liaño Sánchez, María Rosario
author Guemes-Villahoz Noemi
author_facet Guemes-Villahoz Noemi
Talavero González Paula
Porras-Ángel Paloma
Bella Gala, Rafael
Ruiz Pomeda, Alicia
Martín García, Beatriz
Hernández García, Elena
GÓMEZ DE LIAÑO SALGADO, CARMEN NUNILA
Shah Rakhee
García Feijoo, Julián
Gómez De Liaño Sánchez, María Rosario
author_role author
author2 Talavero González Paula
Porras-Ángel Paloma
Bella Gala, Rafael
Ruiz Pomeda, Alicia
Martín García, Beatriz
Hernández García, Elena
GÓMEZ DE LIAÑO SALGADO, CARMEN NUNILA
Shah Rakhee
García Feijoo, Julián
Gómez De Liaño Sánchez, María Rosario
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 617.7-089.243
617.75-053.2
Myopia control
Children
DIMS lenses
Atropine
Óptica y optometría
Óptica oftálmica
Pediatría
2209.15 Optometría
3212 Salud Publica
3201.10 Pediatría
3311.09 Lentes
topic 617.7-089.243
617.75-053.2
Myopia control
Children
DIMS lenses
Atropine
Óptica y optometría
Óptica oftálmica
Pediatría
2209.15 Optometría
3212 Salud Publica
3201.10 Pediatría
3311.09 Lentes
description Aim: To evaluate and compare the efficacy of combination treatment using 0.025% atropine and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses to 0.025% atropine and single vision (SV) spectacle lenses in slowing myopia progression in children with myopia. Methods: Randomised controlled trial conducted on children aged 4-16 years with myopia between -1.00D and -6.00D and astigmatism ≤2.00D. Children were randomly allocated into two groups: 0.025% atropine and SV spectacle lenses treatment group (group A), and 0.025% atropine and DIMS spectacle lenses treatment group (group B). Cycloplegic spherical equivalent refraction (SER) and axial length were measured at baseline, 6 and 12 months. Results: 102 patients completed the 12-month follow-up: n=49 in group A, mean age 9.50±2.78 years and n=53 in group B, mean age 9.90±2.47 years. At 12 months, the mean AL±SD change was 0.18±0.16 mm in group A and 0.07±0.16 mm in group B (mean difference: 0.11, 95% CI: 0.05 to 0.17; p≤0.001). Mean SER±SD progression at 12 months was -0.19±0.42D and -0.09±0.35D in groups A and B, respectively (p=0.13). 39.6% of children in group B had no axial elongation over 12 months compared with 12.2% of the children in group A (p=0.002). Conclusions: Combination treatment with 0.025% atropine and DIMS spectacle lenses is more effective in controlling axial elongation than 0.025% atropine with SV lenses. Although not significant, SER differences between groups were lower in group B. These findings support a potential additive effect of the two treatments.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-08-20
2025
2025-08-20
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/132480
url https://hdl.handle.net/20.500.14352/132480
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMJ Group
publisher.none.fl_str_mv BMJ Group
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416299595038720
score 15.81155

Similares en LA Referencia